Author

Samia Taright

Observed names: S Taright, S. Taright

Institution: Hôpital Mustapha Pacha

Observed institutions: Centre Hospitalo-Universitaire Bab El Oued, Hôpital Mustapha Pacha

OpenAlex ID: A5073541975

Gemcitabine/docetaxel (GD) versus gemcitabine/cisplatin (GC) in stage III/IV non-small cell lung cancer (NSCLC): Preliminary results

2006 · M. Gamaz, T. Makhloufi, et al. · Journal of Clinical Oncology · 4

Correlation between expression of p53, EGFR, cell proliferation defined by Ki67, and survival in stage III/IV non-small cell lung cancer (NSCLC)

2007 · G. B. Malika, K. Bouzid, et al. · Journal of Clinical Oncology · 1

Positivity rate of QuantiFERON-TB Gold Plus ® test among candidates for biotherapy and factors influencing results

2026 · Hanane Mezenner, Hiba Ait Hamoudi, et al. · SAGE Open Medicine

6618 POSTER Gemcitabine and docetaxel in non-small cell lung cancer (NSCLC) and study of prognostic factors

2007 · M. Gamaz, K. Bouzid, et al. · European Journal of Cancer Supplements

P3-176: Prognostic factors for patients with advanced and metastatic non small cell lung cancer (NSCLC): classical factors= performans status (PS), gender and extension of disease; new factors= expression of EGFR, p53 and cell proliferation defined by Ki67

2007 · Malika Gamaz, Kamel Bouzid, et al. · Journal of Thoracic Oncology

Works count: 5

Citation count: 5

H-index: 1

I10-index: